Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05498116
PHASE4

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Sponsor: University of Colorado, Denver

View on ClinicalTrials.gov

Summary

Kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. Inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body releases in response to allergic reactions, may represent a promising therapy to slow the progression of diabetic kidney disease. The current proposal will investigate whether montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early marker of diabetic kidney disease), and improves kidney and cardiovascular function in people with type 1 diabetes and kidney disease.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2023-01-26

Completion Date

2025-10

Last Updated

2025-05-29

Healthy Volunteers

No

Conditions

Interventions

DRUG

Montelukast

10mg daily

OTHER

Placebo

1 capsule daily

Locations (1)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States